Workflow
Sanbo Hospital Management (301293)
icon
Search documents
9月10日晚间重要公告一览
Xi Niu Cai Jing· 2025-09-10 10:38
Group 1 - Dematech won a 900 million yuan overseas smart logistics project from a well-known e-commerce giant in Latin America, focusing on intelligent logistics cross-belt sorting systems and related services [1] - Kang En Bei received approval for the registration of short-term financing bonds and medium-term notes, with a total registration amount of 1 billion yuan, valid for two years [1][2] - Zhi Xiang Jin Tai's GR1803 injection for systemic lupus erythematosus clinical trial has been approved by the National Medical Products Administration [2] Group 2 - Jin Da Wei's subsidiary received approval for a veterinary drug product, pyridone, valid from September 3, 2025, to September 2, 2030 [4] - Fu Li Wang's subsidiary plans to invest 500 million yuan in a high-end wire material project, focusing on high-strength prestressed steel strands for various applications [5] - He Li Biological's subsidiary's Class III medical device registration application has been accepted, focusing on natural bone repair materials [12] Group 3 - Lin Yang Energy won a 244 million yuan metering equipment project from Southern Power Grid, expected to positively impact its 2025 and 2026 performance [20] - Sanxia Water plans to absorb its wholly-owned subsidiary, Chongqing Changdian United Energy, with all assets and liabilities to be inherited by Sanxia Water [13] - Tian Cheng Technology canceled the use of 91 million yuan of raised funds for permanent working capital, ensuring no impact on the normal operation of investment projects [24] Group 4 - Baosteel received approval to publicly issue bonds totaling 20 billion yuan to professional investors, valid for 24 months [52] - Tian Kang Biological reported a 10.15% year-on-year increase in pig sales in August, with a total of 263,800 pigs sold [53] - Xinjiang Construction won multiple major projects totaling 4.506 billion yuan, including a 2.4 billion yuan photovoltaic hydrogen synthesis project [18]
三博脑科股价涨5.02%,南方基金旗下1只基金位居十大流通股东,持有132.95万股浮盈赚取405.51万元
Xin Lang Cai Jing· 2025-09-10 03:01
Group 1 - The core viewpoint of the news is the performance and financial details of Sanbo Brain Science Hospital Management Group Co., Ltd., which saw a stock price increase of 5.02% to 63.85 CNY per share, with a trading volume of 1.113 billion CNY and a turnover rate of 11.23%, resulting in a total market capitalization of 13.152 billion CNY [1] - Sanbo Brain's main business involves providing medical services, with revenue composition being 74.35% from medical services, 25.02% from pharmaceuticals, 0.39% from other supplementary services, and 0.24% from supply chain [1] - The company was established on November 25, 2003, and went public on May 5, 2023, indicating a relatively recent entry into the public market [1] Group 2 - Southern Fund's Southern CSI 1000 ETF (512100) is among the top ten circulating shareholders of Sanbo Brain, having increased its holdings by 249,800 shares in the second quarter, totaling 1.3295 million shares, which represents 0.83% of the circulating shares [2] - The Southern CSI 1000 ETF has a current scale of 64.953 billion CNY and has achieved a year-to-date return of 26.15%, ranking 1602 out of 4223 in its category, and a one-year return of 65.35%, ranking 1153 out of 3780 [2] - The fund manager, Cui Lei, has been in position for 6 years and 300 days, with the fund's total asset scale at 94.976 billion CNY, achieving a best return of 133.3% and a worst return of -18.12% during the tenure [3]
三博脑科拟5700万参设脑科学基金 聚焦脑疾病诊疗等领域
Group 1 - Company plans to invest 57 million yuan in a new fund focused on brain science, aiming to enhance its clinical diagnosis and technological capabilities [1] - The fund aims to raise a total of 300 million yuan, targeting investments in brain disease diagnostics, treatment, health management, and medical information technology [1] - The fund will prioritize companies with technological breakthroughs and independent intellectual property rights in the brain science sector [1] Group 2 - Other limited partners in the fund include various investment firms with a focus on hard technology and healthcare sectors, indicating a diverse investment base [2] - The fund's profit distribution follows a "return of capital first, then dividends" principle, with an 8% annualized return threshold for limited partners [2] - The company emphasizes that the fund's operations will complement its existing medical, educational, and research capabilities, enhancing its competitive edge in the neurology field [3]
三博脑科拟参与投资设立天津元明海河脑科学创业投资合伙企业
Zhi Tong Cai Jing· 2025-09-09 11:26
Group 1 - The company, Sanbo Brain Science (301293.SZ), announced its plan to invest in the establishment of the Tianjin Yuanming Haihe Brain Science Venture Capital Partnership, aiming to enhance its clinical diagnosis and treatment capabilities while leveraging capital market advantages [1][2] - The total amount to be raised by the partnership is set at 300 million yuan, with the company committing 57 million yuan of its own funds to subscribe for partnership shares [1] - The partnership will focus on investing in leading enterprises in the brain science field, particularly in areas such as diagnosis, treatment, health management, and medical information technology, aligning with the company's core business in neurological medical services [2] Group 2 - The investment is expected to create synergies between the company's existing medical services and the targeted investments in advanced brain science technologies and related sectors [2] - The collaboration aims to achieve resource complementarity and broaden investment channels, enhancing the company's competitive edge in the market [2]
三博脑科(301293.SZ)拟参与投资设立天津元明海河脑科学创业投资合伙企业
智通财经网· 2025-09-09 11:22
本次公司参与投资设立基金,一方面可以充分发挥各方优势,实现强强联合、资源互补,为公司带来更 宽阔的投资渠道和发展平台。另一方面,本基金未来聚焦具备临床优势的脑科学领域龙头企业进行投 资,包括但不限于脑疾病的检查与诊断、治疗与监护、健康管理与康复、医疗信息化等方向,重点布局 具有先进技术的脑科学企业及其产业链上下游的细分龙头企业和优质标的,所投方向与公司主业强相 关,可以与公司现有的以神经专科为主的医疗服务业务形成良性协同,为增强三博脑科的持续竞争力添 砖加瓦。 智通财经APP讯,三博脑科(301293.SZ)发布公告,为不断完善公司产业链,不断提升公司的临床诊疗水 平,进一步增强公司的科技赋能,同时为充分利用资本市场平台优势,借助专业投资机构的管理水平和 投资经验,公司拟以有限合伙人身份参与投资设立天津元明海河脑科学创业投资合伙企业(有限合伙)(企 业名称最终以工商管理部门核定为准,以下简称"基金"、"合伙企业"),合伙企业拟募集资金总额为3亿 元,公司拟以自有资金认购5,700万元基金份额。2025年9月9日,公司与天津元明管理咨询合伙企业(有 限合伙)等合作方共同签署了《天津元明海河脑科学创业投资合伙企业 ...
三博脑科(301293.SZ):拟与专业投资机构共同投资设立基金
Ge Long Hui A P P· 2025-09-09 11:16
Core Viewpoint - Sanbo Brain Science (301293.SZ) aims to enhance its clinical diagnosis and treatment capabilities by investing in the Tianjin Yuanming Haihe Brain Science Venture Capital Partnership, with a total fundraising target of 300 million yuan, of which the company will contribute 57 million yuan [1] Investment Strategy - The partnership will primarily invest in the brain science sector, focusing on clinical advantages in sub-sectors such as diagnosis, treatment, monitoring, health management, rehabilitation, and medical information technology [1] - The investment strategy emphasizes breakthrough technologies, proprietary intellectual property, and leading-edge brain science enterprises along with their upstream and downstream industry chain [1]
三博脑科:拟以5700万元认购基金份额 该基金主要投资于脑科学领域
Mei Ri Jing Ji Xin Wen· 2025-09-09 11:12
Core Viewpoint - Sanbo Brain Science (301293) announced its intention to invest as a limited partner in the establishment of Tianjin Yuanming Haihe Brain Science Venture Capital Partnership, aiming to raise a total of 300 million yuan [1] Investment Details - The company plans to invest 57 million yuan of its own funds to subscribe for shares in the fund [1] - The fund will primarily focus on investments in the brain science sector, including projects related to the diagnosis and treatment of brain diseases, health management, rehabilitation, and medical information technology [1] Fund Registration - After the completion of fundraising, the partnership will promptly carry out the private fund registration and filing procedures [1]
三博脑科:拟以5700万元认购天津元明海河脑科学创业投资合伙企业(有限合伙)基金份额
Ge Long Hui A P P· 2025-09-09 11:09
格隆汇9月9日|三博脑科公告,公司拟以有限合伙人身份参与投资设立天津元明海河脑科学创业投资合 伙企业(有限合伙),合伙企业拟募集资金总额为3亿元,公司拟以自有资金认购5700万元基金份额。合 伙企业主要投资于脑科学领域,重点聚焦在具备临床优势的细分赛道,包括但不限于脑疾病的检查与诊 断、治疗与监护、健康管理与康复、医疗信息化等项目标的,重点布局突破技术障碍、拥有自主知识产 权、代表技术前沿的脑科学企业及其产业链上下游的细分龙头企业和优秀企业。合伙期限为十五年,投 资期为自基金成立之日起满三年之日终止。 ...
三博脑科:拟以5700万元认购天津元明海河脑科学创业投资合伙企业(有限合伙)基金份额
人民财讯9月9日电,三博脑科(301293)9月9日晚间公告,公司拟以有限合伙人身份参与投资设立天津 元明海河脑科学创业投资合伙企业(有限合伙),合伙企业拟募集资金总额为3亿元,公司拟以自有资金 认购5700万元基金份额,认缴比例:19%。2025年9月9日,公司与天津元明管理咨询合伙企业(有限合 伙)等合作方共同签署了《天津元明海河脑科学创业投资合伙企业(有限合伙)合伙协议》。合伙企业将主 要投资于脑科学领域,重点聚焦在具备临床优势的细分赛道,包括但不限于脑疾病的检查与诊断、治疗 与监护、健康管理与康复、医疗信息化等项目标的。 ...
三博脑科(301293) - 关于与专业投资机构共同投资设立基金的公告
2025-09-09 10:59
证券代码:301293 证券简称:三博脑科 公告编号:2025-037 三博脑科医院管理集团股份有限公司 关于与专业投资机构共同投资设立基金的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整,没有虚假 记载、误导性陈述或重大遗漏。 一、对外投资概述 1、为不断完善三博脑科医院管理集团股份有限公司(以下简称"公司"、"三 博脑科")产业链,不断提升公司的临床诊疗水平,进一步增强公司的科技赋能, 同时为充分利用资本市场平台优势,借助专业投资机构的管理水平和投资经验, 公司拟以有限合伙人身份参与投资设立天津元明海河脑科学创业投资合伙企业 (有限合伙)(企业名称最终以工商管理部门核定为准,以下简称"基金"、"合 伙企业"),合伙企业拟募集资金总额为 3 亿元,公司拟以自有资金认购 5,700 万元基金份额。2025 年 9 月 9 日,公司与天津元明管理咨询合伙企业(有限合 伙)等合作方共同签署了《天津元明海河脑科学创业投资合伙企业(有限合伙) 合伙协议》(以下简称"合伙协议")。 2、本次对外投资不构成关联交易,亦不构成《上市公司重大资产重组管理 办法》规定的重大资产重组,无需经过公司董事会或股东会的 ...